» Articles » PMID: 34308256

THRIVE Intervention Development: Using Participatory Action Research Principles to Guide a MHealth App-based Intervention to Improve Oncology Care

Overview
Date 2021 Jul 26
PMID 34308256
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Women with hormone receptor-positive, early-stage breast cancer who adhere to adjuvant endocrine therapy (AET) reduce the risk of cancer recurrence and mortality. AET, however, is associated with adverse symptoms that often result in poor adherence. We applied participatory action research (PAR) principles to conduct focus groups and interviews to refine and enhance a web-enabled app intervention that facilitates patient-provider communication about AET-related symptoms and other barriers to adherence.

Methods: We conducted four focus groups with women with early-stage breast cancer on AET (N=28), stratified by race (Black and White) and length of time on AET (<6 months and >6 months), to determine preferences and refine the app-based intervention. A fifth mixed-race focus group was convened (N=6) to refine THRIVE app content using high-fidelity mock-ups and to develop new, tailored feedback messages. We also conducted interviews with oncology nurses (N=5) who participated in the THRIVE randomized controlled trial.

Results: Participants reported preferences for weekly reminder messages to use the THRIVE app, a free-text option to write in AET-related symptoms, and app aesthetics. Other requested app features included: a body map for identifying pain, sleep and dental problems on the symptom list, a dashboard, tailored feedback messages, and information about social support resources. Participants also developed new intervention messages, decided which messages to keep, and edited language for appropriateness and sensitivity. They also discussed the type of electronic pill monitor and incentive plan to be used in the intervention. Nurses reported THRIVE alerts integrated seamlessly into their clinical workflow and increased patient-provider communication, facilitating quicker response to patients' reported symptoms. Nurses reported no negative feedback or usability concerns with the app.

Conclusions: THRIVE app content reflects researchers' partnership with a racially diverse sample of breast cancer survivors and healthcare providers and adherence to participatory design by incorporating patient-requested app features, app aesthetics, and message content. The app has the potential to improve AET adherence and quality of life among breast cancer survivors and reduce disparities in mortality rates for Black women by facilitating communication with healthcare providers.

Citing Articles

Symptom Monitoring App Use Associated With Medication Adherence Among Woman Survivors of Breast Cancer on Adjuvant Endocrine Therapy.

Krukowski R, Hu X, Arshad S, Anderson J, Stepanski E, Vidal G JCO Clin Cancer Inform. 2024; 8:e2400179.

PMID: 39642329 PMC: 11631045. DOI: 10.1200/CCI-24-00179.


Remote Monitoring App for Endocrine Therapy Adherence Among Patients With Early-Stage Breast Cancer: A Randomized Clinical Trial.

Graetz I, Hu X, Kocak M, Krukowski R, Anderson J, Waters T JAMA Netw Open. 2024; 7(6):e2417873.

PMID: 38935379 PMC: 11211959. DOI: 10.1001/jamanetworkopen.2024.17873.


Recruiting hard-to-reach populations via respondent driven sampling for mobile phone surveys in Colombia: a qualitative study.

Solorzano-Barrera C, Rodriguez-Patarroyo M, Torres-Quintero A, Guzman-Tordecilla D, Franco-Rodriguez A, Maniar V Glob Health Action. 2024; 17(1):2297886.

PMID: 38205794 PMC: 10786427. DOI: 10.1080/16549716.2023.2297886.


Silent suffering: the impact of sexual health challenges on patient-clinician communication and adherence to adjuvant endocrine therapy among Black women with early-stage breast cancer.

Anderson J, Paladino A, Blue R, Dangerfield 2nd D, Eggly S, Martin M J Cancer Surviv. 2023; .

PMID: 38114711 PMC: 11216545. DOI: 10.1007/s11764-023-01511-0.


Nurses' Roles in mHealth App Development: Scoping Review.

Bakker C, Wyatt T, Breth M, Gao G, Janeway L, Lee M JMIR Nurs. 2023; 6:e46058.

PMID: 37847533 PMC: 10618897. DOI: 10.2196/46058.


References
1.
Burstein H, Lacchetti C, Anderson H, Buchholz T, Davidson N, Gelmon K . Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J Clin Oncol. 2016; 34(14):1689-701. DOI: 10.1200/JCO.2015.65.9573. View

2.
Sheppard V, Adams I, Lamdan R, Taylor K . The role of patient-provider communication for black women making decisions about breast cancer treatment. Psychooncology. 2010; 20(12):1309-16. DOI: 10.1002/pon.1852. View

3.
Liu Y, Malin J, Diamant A, Thind A, Maly R . Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat. 2012; 137(3):829-36. PMC: 3553239. DOI: 10.1007/s10549-012-2387-8. View

4.
Giunti G, Giunta D, Guisado-Fernandez E, Bender J, Fernandez-Luque L . A biopsy of Breast Cancer mobile applications: state of the practice review. Int J Med Inform. 2018; 110:1-9. DOI: 10.1016/j.ijmedinf.2017.10.022. View

5.
Finitsis D, Vose B, Mahalak J, Salner A . Interventions to promote adherence to endocrine therapy among breast cancer survivors: A meta-analysis. Psychooncology. 2018; 28(2):255-263. DOI: 10.1002/pon.4959. View